Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2024 / Oct / miRNAome Markers of Dementia Disease States
Neurology Neurology Precision medicine

miRNAome Markers of Dementia Disease States

Circulating microRNA levels could be used for the diagnosis of early- and late-stage cognitive impairment as well as Alzheimer’s disease

By Helen Bristow 10/03/2024 News 1 min read

Share

A study published in Alzheimer’s & Dementia has identified plasma microRNA (miRNA) signatures that may aid in early detection of individuals at risk for developing Alzheimer's disease (AD) and predicting the progression from mild cognitive impairment (MCI) to AD. The researchers used data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and analyzed plasma samples from 803 participants, including individuals with early MCI (EMCI), late MCI (LMCI), AD, and cognitively normal controls.

Small RNA sequencing detected 300 miRNAs, which were evaluated by machine learning algorithms to identify signatures associated with different diagnostic stages. The results indicated distinct miRNA signatures that could predict MCI and AD diagnoses. Specifically, a miRNA signature comprising miR-142-3p, miR-98-5p, and miR-9985 was able to predict AD with an accuracy comparable to total Tau (area under curve [AUC] = 0.72 versus AUC = 0.74), while a combination of miR-590-3p, miR-369-3p, and miR-9985 could predict EMCI patients with an AUC of 0.71. For LMCI, a signature of miR-4429, miR-22-5p, and miR-1306 showed similar predictive accuracy (AUC = 0.71).

Additionally, the study highlighted the potential of miRNAs in predicting the conversion from MCI to AD. A miRNA signature of miR-125b-5p, miR-18a-5p, and miR-26b-5p predicted the conversion from EMCI to AD with an AUC of 0.70, outperforming traditional cerebrospinal fluid (CSF) biomarkers. Similarly, a signature of miR-338-3p, miR-584-5p, and miR-142-3p was able to predict LMCI to AD conversion with an AUC of 0.75.

These miRNA signatures were also analyzed for their involvement in specific molecular pathways relevant to AD pathogenesis. The team found that the miRNAs associated with cognitive decline (EMCI and LMCI) regulate pathways related to synaptic plasticity, mitochondrial dysfunction, and neuroinflammation – all of which are critical in the development and progression of AD. Interestingly, some pathways were unique to specific stages of the disease, highlighting the potential of miRNA profiling to offer more targeted diagnostic tools.

Overall, the study demonstrates that plasma miRNA signatures, combined with cognitive assessments, could enhance early detection of at-risk individuals and improve the accuracy of predicting disease progression, potentially reducing the need for invasive tests, such as CSF analysis. Further validation in more diverse populations and longitudinal studies is needed to confirm the clinical applicability of these findings.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Helen Bristow

Combining my dual backgrounds in science and communications to bring you compelling content in your speciality.

More Articles by Helen Bristow

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

The Shapeshifting Cancer
Neurology
The Shapeshifting Cancer

February 24, 2022

1 min read

Understanding the heterogeneity and plasticity of glioblastoma

Image of the Month
Neurology
Image of the Month

October 21, 2016

1 min read

Who Will Be The Caretakers?
Neurology
Who Will Be The Caretakers?

August 4, 2022

3 min read

Recent allegations of image manipulation in a major Alzheimer’s disease paper reaffirm the importance of research integrity

Getting to the Genetic Core of Autism
Neurology
Getting to the Genetic Core of Autism

August 15, 2022

2 min read

Investigating the genotype-phenotype relationship in autism to improve our understanding of heterogeneity

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.